Active Ingredient History
Seractide is a polypeptide hormone corresponding to thirty-nine amino acids of human corticotropin that differs from full-length human corticotropin at four positions. Seractide is potent endogenous melanocortin receptor 2 (MC ) agonist. Seractide stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Seractide, was approved by FDA in 1978, but was never marketed. The Seractide, that was ultimately withdrawn by FDA in 2014 for safety reasons. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adrenal Cortex Diseases (Phase 1)
Adrenal Gland Diseases (Phase 4)
Adrenal Insufficiency (Phase 4)
Adrenocorticotropic Hormone (Phase 2/Phase 3)
Amyotrophic Lateral Sclerosis (Phase 2)
Anemia (Phase 3)
Arthritis, Psoriatic (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Cholesterol (Early Phase 1)
Coronary Artery Disease (Phase 4)
Deficiency Diseases (Phase 3)
Dermatomyositis (Phase 4)
Diabetic Nephropathies (Phase 4)
Diet, Ketogenic (Phase 2/Phase 3)
Drugs, Investigational (Early Phase 1)
Dry Eye Syndromes (Phase 4)
Epilepsy (Phase 2)
Fibrosis (Phase 3)
Gastrointestinal Motility (Phase 4)
Glomerulonephritis (Phase 4)
Glomerulonephritis, IGA (Phase 4)
Glomerulonephritis, Membranous (Phase 4)
Glomerulosclerosis, Focal Segmental (Phase 4)
Growth and Development (Phase 3)
Healthy Volunteers (Phase 4)
Hyperaldosteronism (Phase 4)
Hypertension (Early Phase 1)
Hypopituitarism (Phase 4)
Infant (Phase 1)
Keratitis (Phase 4)
Keratoconjunctivitis Sicca (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 1)
Kidney Transplantation (Phase 4)
Lupus Erythematosus, Systemic (Phase 4)
Lupus Nephritis (Phase 4)
Macular Edema (Phase 4)
Migraine Disorders (Phase 2)
Mitral Valve Insufficiency (Phase 4)
Multiple Sclerosis, Chronic Progressive (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Muscular Dystrophy, Duchenne (Phase 2)
Nephrotic Syndrome (Phase 4)
Optic Neuritis (Early Phase 1)
Organ Transplantation (Phase 4)
Panuveitis (Phase 4)
Polycystic Ovary Syndrome (Early Phase 1)
Polymyositis (Phase 2)
Post-Dural Puncture Headache (Phase 4)
Proteinuria (Phase 4)
Psychological Distress (Phase 4)
Receptors, Corticotropin (Phase 4)
Respiratory Distress Syndrome (Phase 2)
Retinal Vasculitis (Phase 4)
Sarcoidosis (Phase 4)
Sarcoidosis, Pulmonary (Phase 4)
Scleritis (Phase 4)
Sclerosis (Phase 4)
Sleep Disorders, Intrinsic (Phase 1)
Spasms, Infantile (Phase 4)
Uveitis (Phase 4)
Uveitis, Anterior (Phase 4)
Uveitis, Intermediate (Phase 4)
Uveitis, Posterior (Phase 4)
Vitreoretinopathy, Proliferative (Early Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue